title: Use of mifepristone and sublingual misoprostol for early medical abortion.
abstract: OBJECTIVE
  Existing drug-induced abortion techniques involve oral administration of 200 mg of mifepristone, followed by oral administration of 600 microg of misoprostol 48 hours later, but the effects are variable. As revealed by recent research, sublingual and oral administrations of misoprostol are equally efficacious in terms of rapid absorption, but the former lasts longer in serum. Hence, in the near future, sublingual administration of misoprostol may become the most effective way to induce abortion.
  
  
  METHODS
  Women with intrauterine pregnancy up to 49 gestational days received vaginal ultrasonography, followed by oral administration of mifepristone 200 mg and sublingual administration of misoprostol 600 microg 48 hours later. They returned for follow-up consultations 3 and 14 days after. The definition of a successfully induced complete medical abortion was that the abortion occurred without surgery or evacuating the uterus.
  
  
  RESULTS
  A total of 356 women underwent medical abortion; the complete abortion rate was 98.3% (350 women). Medical abortion was unsuccessful in five (1.7%) women, who eventually had to undergo dilation and curettage. Patients found the side effects to be bearable; the reported satisfaction rate was 89.9% (325 women).
  
  
  CONCLUSIONS
  Medical abortion for early termination of pregnancy should be achieved by oral administration of mifepristone, followed by sublingual administration of misoprostol.
authors.affiliation: Department of Obstetrics and Gynecology, Kuo General Hospital, Tainan, Taiwan.
authors.forename: Mau
authors.initials: M
authors.lastname: Lin
authors.forename: Yiu-Tai
authors.initials: YT
authors.lastname: Li
authors.forename: Fu-Min
authors.initials: FM
authors.lastname: Chen
authors.forename: Shu-Fang
authors.initials: SF
authors.lastname: Wu
authors.forename: Ching-Wan
authors.initials: CW
authors.lastname: Tsai
authors.forename: Tien-Hui
authors.initials: TH
authors.lastname: Chen
authors.forename: Tsung-Cheng
authors.initials: TC
authors.lastname: Kuo
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000021:Abortifacient Agents, Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000028:Abortion, Induced / Q000379:methods*; D000282:Administration, Intravaginal; D000286:Administration, Sublingual; D000293:Adolescent; D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage* / Q000009:adverse effects; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects; D011247:Pregnancy; D011261:Pregnancy Trimester, First
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D016595:Misoprostol; D015735:Mifepristone